{"id":5396,"date":"2022-09-07T06:29:09","date_gmt":"2022-09-07T13:29:09","guid":{"rendered":"https:\/\/allocare.caredx.com\/?p=5396"},"modified":"2022-09-07T06:29:18","modified_gmt":"2022-09-07T13:29:18","slug":"is-metformin-now-in-our-armamentarium-for-autosomal-dominant-polycystic-kidney-disease-adpkd","status":"publish","type":"post","link":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2022\/09\/07\/is-metformin-now-in-our-armamentarium-for-autosomal-dominant-polycystic-kidney-disease-adpkd\/","title":{"rendered":"Is Metformin Now in Our Armamentarium for Autosomal Dominant Polycystic Kidney Disease (ADPKD)?"},"content":{"rendered":"<span class=\"simplefavorite-button has-count loading\" data-postid=\"5396\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>\n<p>Treatment options for autosomal dominant polycystic kidney disease (ADPKD) are sparse despite the detrimental course of the disease. Tolvaptan, a vasopressin V2 receptor (V2R) antagonist, is the only FDA approved treatment so far to decelerate decline in glomerular filtration rate (GFR) in ADPKD. There has been a pressing need for additional therapeutic strategies that can prevent kidney enlargement and progression to end-stage kidney disease (ESKD), which occurs in almost half of the patients with ADPKD. In that regard, metformin has been investigated in preclinical and clinical studies with a proposed mechanism of AMP-activated protein kinase (AMPK) activation.<\/p>\n\n\n\n<p>For the past 20 years, researchers have used rodent models of ADPKD to investigate efficacious therapies for ADPKD. <a href=\"https:\/\/ajkdblog.org\/2022\/09\/07\/is-metformin-now-in-our-armamentarium-for-autosomal-dominant-polycystic-kidney-disease-adpkd\/\">Read the full article<\/a> in the American Journal of Kidney Diseases blog.<\/p>\n<span class=\"simplefavorite-button has-count loading\" data-postid=\"5396\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>","protected":false},"excerpt":{"rendered":"<p>Loading Treatment options for autosomal dominant polycystic kidney disease (ADPKD) are sparse despite the detrimental course of the disease. Tolvaptan, a vasopressin V2 receptor (V2R) antagonist, is the only FDA &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2022\/09\/07\/is-metformin-now-in-our-armamentarium-for-autosomal-dominant-polycystic-kidney-disease-adpkd\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Is Metformin Now in Our Armamentarium for Autosomal Dominant Polycystic Kidney Disease (ADPKD)?&#8221;<\/span><\/a><\/p>\n","protected":false},"author":208,"featured_media":3832,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":0,"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","_ecp_custom_2":"","footnotes":""},"categories":[2],"tags":[1008,1009,957,1010],"post_format":[],"Dislikes":"","Likes":"","simplefavorites_count":"","views":"1417","post_likes_plusCounter":"","post_dislikes_plusCounter":"","acf":[],"_links":{"self":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/5396"}],"collection":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/users\/208"}],"replies":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/comments?post=5396"}],"version-history":[{"count":1,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/5396\/revisions"}],"predecessor-version":[{"id":5397,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/5396\/revisions\/5397"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media\/3832"}],"wp:attachment":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media?parent=5396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/categories?post=5396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/tags?post=5396"},{"taxonomy":"post_format","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/post_format?post=5396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}